Valeant is a BuyThey could sell off one business unit for 20 billion, pay off 2/3 of their debt, and only take a 25% hit to their bottom line. There are so many ways they could do this. This company is making like 8-11 billion in revenue per year, and its market cap is 12 billion. All the metrics point towards a buy. Congress is not going to tell businesses they cant raise the price on their products no matter how much they dont like it. That would be a huge blow to the innovation/incentive of the pharmaseutical industry. It going to be a yelling match, and then Valeant is going to continue to make billions.